Press Release
AB-Therapeutics participates in the 10th Venture Capital Forum NEOTEC
AB-Therapeutics, located at the UAB Research Park, will have the opportunity to meet investors and secure funding for the development of new drugs for the treatment of lung cancer and pancreatic cancer.
The 10 th NEOTEC Venture Capital Forum is a forum where investors and technology companies in funding rounds meet. AB-Therapeutics has been one of the 15 companies selected to participate in this forum, where they will have the opportunity to present their project to potential investors.
AB-Therapeutics is seeking investors for its first round of funding. 85% of the funds will be invested in the preclinical and clinical development of drug candidates to treat lung cancer and pancreatic cancer, through outsourcing to contract research organizationa (CRO). Only 15% of the costs will be allocated to overhead and human resources.
The spin-off has a new therapeutic approach for cancer of the lung and pancreas, Multitarget Lipid Signaling, which alters the dynamics of multiple proteins in the cell membrane and has a much lower toxicity compared to classical chemotherapy.
NEOTEC Venture Capital Forum will be held on November 10 in La Rioja, organized by the Center for Industrial Technological Development (CDTI), the Economic Development Agency of La Rioja and RedOTRI, and collaboration, among others, ACC1Ó and the Association of Technology Parks of Spain (APTE).
The 10 th NEOTEC Venture Capital Forum is a forum where investors and technology companies in funding rounds meet. AB-Therapeutics has been one of the 15 companies selected to participate in this forum, where they will have the opportunity to present their project to potential investors.
AB-Therapeutics is seeking investors for its first round of funding. 85% of the funds will be invested in the preclinical and clinical development of drug candidates to treat lung cancer and pancreatic cancer, through outsourcing to contract research organizationa (CRO). Only 15% of the costs will be allocated to overhead and human resources.
The spin-off has a new therapeutic approach for cancer of the lung and pancreas, Multitarget Lipid Signaling, which alters the dynamics of multiple proteins in the cell membrane and has a much lower toxicity compared to classical chemotherapy.
NEOTEC Venture Capital Forum will be held on November 10 in La Rioja, organized by the Center for Industrial Technological Development (CDTI), the Economic Development Agency of La Rioja and RedOTRI, and collaboration, among others, ACC1Ó and the Association of Technology Parks of Spain (APTE).
LATEST NEWS
09.09.2024
Press Release
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024
Press Release
AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
16.07.2024
Press Release
AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info
11.03.2024
Press Release
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023
Press Release
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022
Press Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022
Press Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022
Press Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
